to CRY product family. The value will be unlocked quickly in complimentary offerings. The current Medafor executive team appears amateurish and in over their heads--trying to draw their salaries for as long as they can and doing their shareholders a huge disservice.
If they were smart, they would buy Cryolife shares with their severance and ride this thing to $15+/share.
$2/share is not likely to buy many more Medafor shares. The 1.6 million shares purchased were probably founder shares with a basis of a nickel. Most Medafor shareholders own their stock at $2/share. If this deal happens, CRY will have to "pony up". My guess is Medafor is not for sale below $6-$8/share. CRY will have trouble buying Medafor, because CRY stock is cheap...because of CRY's slow sales growth. CRY is unlikely to force Medafor to the table either, because Medafor is now profitable enough to fight CRY to a stand still. SGA, if you want to buy Medafor, get reasonable with your offer, because. Your $2/share offer isn't even in the ball park. If Medafor was part of CRY, CRY's revenue multiplier would probably double overnight. SO CRY shareholders, don't get too excited. The information CRY is putting out is only a small part of the real story.
Of course it is fair value. What multiples do you think you think medafor should get? The company has been flailing. Getting cryolife shares with the purchase will return a much bigger investment for medafor shareholders.
Sorry you don't make any sense--a nickel share basis, therefore therefore those shares were just given to CRY for a fraction of their true value? Again your logic is flawed. If you had gold at $200/oz, you'd probably sell if you someone offered you $400/oz.
current offer would = $2.(cash) and $6.61(shs)by your figures that would be just right! good deal for all, and less headache and hassle for medafor(being publicly owned has its own set of headaches, past day to day mgmt of humans in the workplace.
Cry is a privately held company in Minneapolis. I assume that our poster, dihild of St. Paul, is a party in one of the two rounds of funding that supported Medafor and is privy to insider info that is not available to us mere retail stock market investors.
I own shares of both companies. In my view Medafor management is doing just fine. They have grown sales at 60% a year for the past 3 years. The next 3 years look great too. On the other hand, what was CRY's sales growth rate over this period...perhaps 10% a year...? Think about what this metric does over time. Now ask yourself which company is better managed.